Neurotech International Ltd
ASX:NTI
Intrinsic Value
Neurotech International Ltd. engages in the research, designing, marketing, and through third party manufacturers, production of wearable neurotechnology devices to assist with neurological conditions... [ Read More ]
The intrinsic value of one NTI stock under the Base Case scenario is 0.01 AUD. Compared to the current market price of 0.09 AUD, Neurotech International Ltd is Overvalued by 93%.
Valuation Backtest
Neurotech International Ltd
Run backtest to discover the historical profit from buying and selling NTI stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Neurotech International Ltd
Current Assets | 5.3m |
Cash & Short-Term Investments | 5m |
Receivables | 257.6k |
Other Current Assets | 24.6k |
Non-Current Assets | 870 |
PP&E | 870 |
Current Liabilities | 1.3m |
Accounts Payable | 1.3m |
Earnings Waterfall
Neurotech International Ltd
Revenue
|
1.3m
AUD
|
Cost of Revenue
|
0
AUD
|
Gross Profit
|
1.3m
AUD
|
Operating Expenses
|
-9m
AUD
|
Operating Income
|
-7.8m
AUD
|
Other Expenses
|
0
AUD
|
Net Income
|
-7.8m
AUD
|
Free Cash Flow Analysis
Neurotech International Ltd
NTI Profitability Score
Profitability Due Diligence
Neurotech International Ltd's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
Score
Neurotech International Ltd's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
NTI Solvency Score
Solvency Due Diligence
Neurotech International Ltd's solvency score is 71/100. The higher the solvency score, the more solvent the company is.
Score
Neurotech International Ltd's solvency score is 71/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NTI Price Targets Summary
Neurotech International Ltd
Shareholder Return
NTI Price
Neurotech International Ltd
Average Annual Return | 49.69% |
Standard Deviation of Annual Returns | 83.79% |
Max Drawdown | -89% |
Market Capitalization | 78.7m AUD |
Shares Outstanding | 917 388 992 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Neurotech International Ltd. engages in the research, designing, marketing, and through third party manufacturers, production of wearable neurotechnology devices to assist with neurological conditions such as autism. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2016-11-04. The firm operates through its wholly owned, Malta-based subsidiary AAT Research Limited. The firm is focusing on neuro-protective, anti-inflammatory and neuro-modulatory activities of NTI/Dolce cannabis strains. The firm through its class II device Mente is focused on development and commercialisation of technological solutions for the screening and treatment of symptoms associated with conditions such as autism. Mente is, a home therapy that is clinically proven to increase engagement and relaxation in autistic children with elevated Delta band brain activity.
Contact
IPO
Employees
Officers
The intrinsic value of one NTI stock under the Base Case scenario is 0.01 AUD.
Compared to the current market price of 0.09 AUD, Neurotech International Ltd is Overvalued by 93%.